b3(fv)-pe38
mAbexperimentalADC
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 1997 (NCT00003020)
Timeline
1990s
- Jan 1, 1997
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Lewis Y antigenBINDING AGENT
Lewis Y antigen binding agent
- Elongation factor 2INHIBITOR
Elongation factor 2 inhibitor
- Lewis Y antigenImmunity, passive
Lewis Y antigen immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- Pseudomonas exotoxin A
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109307 ↗
Also known as
- b3(fv)-pe38
- immunotoxin lmb-7
- lmb-7
- lmb-7
- lmb-7
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00003020 | Phase 1 | Sep 1, 1997 | Duke University, National Cancer Institute (NCI) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Duke University | Academic/Hospital | 1 | 1 | 1 | 1997 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 1997 |
2 organizations
Page 1 / 1